Comparative Pharmacology
Head-to-head clinical analysis: AMEN versus NORGESTIMATE ETHINYL ESTRADIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMEN versus NORGESTIMATE ETHINYL ESTRADIOL.
AMEN vs NORGESTIMATE; ETHINYL ESTRADIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone receptor agonist; induces secretory endometrium, inhibits gonadotropin release, and alters cervical mucus.
Combination oral contraceptive containing norgestimate (a progestin) and ethinyl estradiol (an estrogen). The primary mechanism is suppression of gonadotropins (FSH and LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, preventing ovulation. Additional effects include thickening cervical mucus (inhibiting sperm penetration) and altering endometrial receptivity.
Medroxyprogesterone acetate (AMEN): 5-10 mg orally once daily for 5-10 days, starting on day 16 or 21 of menstrual cycle; also 150 mg IM every 3 months for contraception.
Oral, one tablet daily at the same time for 21 days, followed by 7 placebo tablets.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours. In severe hepatic impairment, half-life may be prolonged up to 12 hours.
Norgestimate: terminal half-life of norelgestromin (active metabolite) is 27.6 ± 7.8 hours; ethinyl estradiol: terminal half-life is 17.5 ± 6.3 hours. Steady state achieved within 14 days.
Primarily hepatic metabolism to inactive metabolites, with <1% excreted unchanged in urine. Fecal elimination of metabolites accounts for ~30%.
Norgestimate metabolites are primarily excreted via urine (60-80%) and feces (35-49%) as glucuronide and sulfate conjugates; ethinyl estradiol is excreted in urine (40%) and feces (60%) as conjugates.
Category C
Category D/X
Progestin
Progestin + Estrogen